MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

InflaRx NV

Fechado

0.81 2.53

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.81

Máximo

0.86

Indicadores-chave

By Trading Economics

Rendimento

-3.2M

-8.3M

Margem de lucro

1,208,456.738

Funcionários

74

EBITDA

-3.2M

-8.2M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+520.69% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-58M

55M

Abertura anterior

-1.72

Fecho anterior

0.81

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

InflaRx NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de jul. de 2025, 21:01 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 20:46 UTC

Ganhos

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 de jul. de 2025, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 20:36 UTC

Ganhos

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 de jul. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 de jul. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 20:02 UTC

Conversa de Mercado

Gold Higher to Close Out Week -- Market Talk

18 de jul. de 2025, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 de jul. de 2025, 19:06 UTC

Conversa de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 de jul. de 2025, 18:24 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 de jul. de 2025, 18:19 UTC

Ganhos

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 de jul. de 2025, 18:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 de jul. de 2025, 18:11 UTC

Ganhos

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 de jul. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 de jul. de 2025, 16:29 UTC

Conversa de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 de jul. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 16:04 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 de jul. de 2025, 15:47 UTC

Conversa de Mercado
Ganhos

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparação entre Pares

Variação de preço

InflaRx NV Previsão

Preço-alvo

By TipRanks

520.69% parte superior

Previsão para 12 meses

Média 5.4 USD  520.69%

Máximo 10 USD

Mínimo 2 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para InflaRx NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

5

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.29 / 1.85Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Neutral Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.